Prometheus Biosciences to Participate at November Healthcare Conferences

Rhea-AI Summary

Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company focused on precision medicine for immune-mediated diseases, will present at three upcoming healthcare conferences. Management will conduct fireside chats at the Credit Suisse Annual Healthcare Conference on November 8, the Guggenheim 4th Annual Immunology and Neurology Conference on November 15, and the Jefferies London Healthcare Conference on November 17. Webcast access will be available through the Prometheus Biosciences Investor Relations page.

SAN DIEGO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today announced that management will conduct fireside chats at the following healthcare conferences:

Credit Suisse Annual Healthcare Conference
Date: Tuesday, November 8, 2022
Time: 12:50 pm EST

Guggenheim 4th Annual Immunology and Neurology Conference
Date: Tuesday, November 15, 2022
Time: 11:20 am EST

Jefferies London Healthcare Conference
Date: Thursday, November 17, 2022
Time: 9:10 am GMT

A live and archived webcast of the fireside chats will be available via the Events & Webcasts page on the Investor section of the Prometheus Biosciences website.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360^TM, combines proprietary machine learning-based analytical approaches with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.

About PRA023: Pipeline in a Product Candidate

The Company’s lead candidate, PRA023, is an IgG1 humanized monoclonal antibody that has been shown to block tumor necrosis factor (TNF)-like ligand 1A (TL1A). PRA023 binds both soluble and membrane-associated human TL1A with high affinity and specificity and has the potential to substantially improve outcomes for moderate-to-severe IBD patients predisposed to increased TL1A expression. Prometheus is developing PRA023 for the treatment of immune-mediated diseases including ulcerative colitis (UC), Crohn’s Disease (CD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).

The Company is currently conducting three Phase 2 studies of PRA023: a Phase 2 trial in UC patients, ARTEMIS-UC, a Phase 2a trial in CD patients, APOLLO-CD, and a Phase 2 trial in SSc-ILD, ATHENA-SSc-ILD, each utilizing a genetic-based companion diagnostic candidate designed to identify patients who are predisposed to increased expression of TL1A and therefore potentially more likely to respond to PRA023.

Prometheus Biosciences Contact:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com

FAQ

What is Prometheus Biosciences planning at the Credit Suisse Annual Healthcare Conference on November 8, 2022?

Prometheus Biosciences will conduct a fireside chat at the Credit Suisse Annual Healthcare Conference on November 8, 2022, at 12:50 pm EST.

When will Prometheus Biosciences present at the Guggenheim 4th Annual Immunology and Neurology Conference?

Prometheus Biosciences will present at the Guggenheim 4th Annual Immunology and Neurology Conference on November 15, 2022, at 11:20 am EST.

What is the date and time for Prometheus Biosciences' fireside chat at the Jefferies London Healthcare Conference?

The fireside chat at the Jefferies London Healthcare Conference will take place on November 17, 2022, at 9:10 am GMT.

How can I access the webcasts of Prometheus Biosciences' upcoming presentations?

Webcasts of Prometheus Biosciences' presentations will be available live and archived on their Investor Relations website.

What is the focus of Prometheus Biosciences' therapeutic pipeline?

Prometheus Biosciences focuses on precision medicine for immune-mediated diseases, with its lead candidate, PRA023, targeting conditions like ulcerative colitis and Crohn's Disease.